Current status of poly(ADP-ribose) polymerase inhibitors and future directions

• Main Authors: Ohmoto A, Yachida S
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-10-01
• Series: OncoTargets and Therapy
• Subjects: Poly (ADP-ribose) inhibitors; synthetic lethality; BRCA mutation; homologous recombination; drug resistance; biomarkers
• Online Access: https://www.dovepress.com/current-status-of-polyadp-ribose-polymerase-inhibitors-and-future-dire-peer-reviewed-article-OTT

Akihiro Ohmoto,1 Shinichi Yachida1,2 1Laboratory of Clinical Genomics, National Cancer Center Research Institute, Tokyo, 2Department of Cancer Genome Informatics, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan Abstract: Inhibitors of poly(ADP-ribose) polymerases (PARPs), which play a key role in DNA damage/repair pathways, have been developed as antitumor agents based on the concept of synthetic lethality. Synthetic lethality is the idea that cell death would be efficiently induced by simultaneous loss of function of plural key molecules, for example, by exposing tumor cells with inactivating gene mutation of BRCA-mediated DNA repair to chemically induced inhibition of PARPs. Indeed, three PARP inhibitors, olaparib, rucaparib and niraparib have already been approved in the US or Europe, mainly for the treatment of BRCA-mutant ovarian cancer. Clinical trials of various combinations of PARP inhibitors with cytotoxic or molecular-targeted agents are also underway. In particular, expanded applications of PARP inhibitors are anticipated following recent reports that defects in homologous recombination repair (HRR) are associated with mutations in repair genes other than BRCA1/BRCA2, such as ATM, ATR, PALB2, RAD51, CHEK1 and CHEK2, as well as with epigenetic loss of BRCA1 function through promoter methylation or overexpression of the BRCA2-interacting transcriptional repressor EMSY. Current topics of interest include selection of the best agent in each clinical context, identification of new treatment targets for HRR-proficient cases, and development of PARP inhibitor-based regimens that are less toxic and that prolong overall survival as well as progression-free survival. In addition, potential long-term side effects and suitable biomarkers for predicting efficacy and mechanisms of clinical resistance are in discussion. This review summarizes representative preclinical and clinical data for PARP inhibitors and discusses their potential for future applications to treat various malignancies. Keywords: PARP inhibitors, synthetic lethality, BRCA mutation, homologous recombination, drug resistance, biomarkers